Arcadia Biosciences Inc   (RKDA)
Other Ticker:  
Price: $0.3362 $0.01 1.879%
Day's High: $0.345 Week Perf: -3.67 %
Day's Low: $ 0.33 30 Day Perf: -1.98 %
Volume (M): 47 52 Wk High: $ 2.66
Volume (M$): $ 16 52 Wk Avg: $0.95
Open: $0.33 52 Wk Low: $0.30

 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 25
 Employees 47
 Revenues (TTM) (Millions $) 11
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Arcadia Biosciences Inc

We, a corporation formed in 2002, are an agricultural biotechnology trait company engaged in the development of traits that improve food, feed and fiber crops and enhance the value of the resulting agricultural products. Our customers include seed companies who incorporate these traits into their elite varieties to increase the value of a crop for farmers, as well as food and feed companies who make products that increase the choices and nutritional value of foods for consumers.

We are focused on two distinct areas of the agricultural supply chain:

Improvement of crop yield by mitigating the impacts of abiotic stresses such as drought, heat, nutrient deficiency, water scarcity, and soil salinity. These stresses are prevalent in most agricultural environments with varying degrees of severity and often have material consequences on crop production, quality, and farmer incomes. Our traits have been introgressed into several crops, including rice, wheat, and soybeans, and we have demonstrated significant yield improvements in multiple years of field testing. In addition to improving the efficiency of agricultural productions, these traits also have the potential of reducing the impact of agriculture on the environment by lowering water requirements and reducing the occurrence of excess nitrogen runoff from intensive farming.

Enhancement of the nutritional quality of crops by changing the compositional quality of oilseeds and grains. We currently produce and market the SONOVA® brand of oil containing Gamma Linolenic Acid (GLA), an omega-6 fatty acid derived from safflower. We recently received GRAS notification (generally recognized as safe) from the FDA for use of SONOVA GLA safflower oil in medical foods and nutritional beverages, which we expect will expand the market for this product. In addition, we are in late stage development of Resistant Starch (RS) wheat, a product with twice as much fiber content as conventional wheat. This and other wheat quality products in our pipeline are being developed using our non-transgenic TILLING technology platform.

Our business model is to access trait technologies that have already achieved proof of concept whether in a public research program or with commercial partners. We further develop these technologies by optimizing their function and validating their performance through intensive field trial testing in multiple crops under varying growth conditions, thereby better establishing commercial viability for resulting products. We then license our technologies to major seed and consumer product companies who perform additional testing and product development and, where needed, generate the requisite data to support regulatory submissions and approvals. License agreements with our partners may include financial and non-financial milestones. When products containing our traits are commercialized we will receive a share of the revenue. In select instances, we also work with our commercial partners to make the regulatory filings required to support commercial launch of the traits in order to increase our share of the revenue.

We use both genetically modified, or GM, and non-GM technologies to develop our traits. This approach allows us to select the most appropriate technology for development of a particular trait, crop and market. However, a key component of the development cycle of GM traits is that U.S., or in some instances, global deregulation of the trait by one or more regulatory agencies may be required. As there continues to be a significant debate about the role of GM traits in agricultural crops, we have seen this issue begin to impact some regulatory agencies which exercise control over the pace of deregulation of products, thereby allowing commercialization. We have recently experienced delays in the review of many of our high value traits principally due to inaction from these government regulatory authorities. For example, in India, where regulators have not approved field trials for testing of GM traits for the last two years, we estimate the impact to trait development and crop commercialization timelines of our license partner in India, Maharashtra Hybrid Seeds Company Ltd. (“Mahyco”), could be at least two to three year delay.

   Company Address: 202 Cousteau Place Davis 95618 CA
   Company Phone Number: 756-7077   Stock Exchange / Ticker: NASDAQ RKDA
   RKDA is expected to report next financial results on March 30, 2023.

Customers Net Income fell by RKDA's Customers Net Profit Margin fell to

-3.19 %

7.4 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AVD        2.16% 
CF   -3.89%    
MHDG   -3.89%    
MOS   -4.75%    
SANW        4.67% 
CVI   -13.87%    
• View Complete Report

Medtronic Plc

Sharp slump in EPS at the Medical Equipment & Supplies company all along the financial span ending October 28 2022

For the financial span ending October 28 2022 Medtronic Plc earnings per share dived by -67.01 % of $0.32 per share compare to $0.97 a year before and profit plummeted by -54.29 % from $0.70 per share from the prior reporting period.

Sales contracted by -3.339 % to $7.59 billions from $7.85 billions in the similar reporting period a year before and sequentially Sales advanced by 2.903 % from $7.37 billions.

Commonwealth Income And Growth Fund Vii Lp

The Rental & Leasing company declared that it has encountered astonishing obstacles, all along the financial third quarter of 2022

For the fiscal span ending September 30 2022 company Deficit has extended of $-0.03 per share compare to $-0.02 a year prior and Income per Share improved from $-0.13 per share from the previous financial reporting period.

Sales faded by -40.882 % to $0.23 millions from $0.38 millions in the comparable financial reporting period a year prior and sequentially Sales grew by 0.82 % from $0.22 millions.

Lands End Inc

Almost uneventful times at Lands End Inc during the financial third quarter of 2022

Declining demand led to diminishing Returns in the fiscal interval closing October 28 2022, Sales sunk by -1.293 % to $370.98 millions and deficit per share was at $-0.14 compared to $0.22 per share saw in the quarter a year before.

Gex Management Inc

In spite of the boost in Sales Profitability not Reached by the company over the financial second quarter of 2022

Gex Management Inc announced in the financial second quarter of 2022 surge in Sales by 23.731 % to $0.48 millions from the similar reporting period a year prior, but it has reached balanced books at $0.00 per share.

Avepoint Inc

Redemption of Diminishing Returns at the Avepoint Inc amid the most recent fiscal period

For the most recent fiscal period AVPT decreased a loss per share of $-0.04 per share compare to $-0.05 a year ago and Income per Share improved from $-0.05 per share from the preceding financial reporting period.

Sales rose in double digits by 16.341 % to $62.74 millions from $53.93 millions in the comparable financial reporting period a year ago and sequentially Sales advanced by 12.635 % from $55.70 millions.


Arcadia Biosciences Inc 's Segments
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

MDEX's Profile

Stock Price

MDEX's Financials

Business Description


Charts & Quotes

MDEX's News


MDEX's Competitors

Customers & Markets

Economic Indicators

MDEX's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071